EUVIMEDEUVIMED entdecken
Crossref

Nivolumab dose stewardship in routine oncology practice: a real-world health-economic simulation

Arif Hakan Önder iD, Mehmet Mutlu Çatlı, Olgun Keskin

Expert Review of Pharmacoeconomics & Outcomes Research · 02.11.2026 · 1-11

DOI: 10.1080/14737167.2026.2757915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 02.11.2026. Verfasst von Arif Hakan Önder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Türkiye. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors improve outcomes across solid tumors but increase oncology drug expenditure. This study estimated the impact of a predefined nivolumab dose stewardship algorithm on drug utilization, nivolumab drug cost, and vial waste. RESEARCH DESIGN AND METHODS: We performed a single-center retrospective drug-cost and resource-utilization simulation using real-world data from adults who received nivolumab between 2024 and 2026. Observed dosing was compared with a modeled policy incorporating weight-informed dosing, vial-based dose rounding, and preservation of protocol-mandated fixed-dose regimens. Clinical outcomes and adverse events were not assessed; clinical equivalence was assumed for modeling purposes but not demonstrated. RESULTS: Among 102 patients, median age was 64 years, body weight was 70 kg, and exposure was 9.5 cycles. The modeled policy reduced nivolumab consumption from 432,360 mg to 342,360 mg, saving 90,000 mg (20.8%). Estimated nivolumab drug cost decreased from 221,040,980 TL to 175,029,119 TL, saving 46,011,861 TL. Vial waste decreased from 43,360 mg to 2,000 mg, a 95.4% reduction. CONCLUSIONS: This retrospective simulation suggests that a predefined nivolumab dose stewardship algorithm may reduce drug use, drug cost, and vial waste. Prospective studies are required before clinical implementation.

Schlagwörter

Stichwörter der Autor:innen

Nivolumabbudget impactdose stewardshipdrug-cost analysisimmune checkpoint inhibitorreal-world dataresource utilizationvial waste

Autor:innen und Institutionen

  • Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Türkiye.
  • Department of Pulmonology, Antalya Education and Research Hospital, Antalya, Türkiye.

ORCID-Profile: Arif Hakan Önder

Zitieren

APA

Önder, A. H., Çatlı, M. M., & Keskin, O. (2026). Nivolumab dose stewardship in routine oncology practice: a real-world health-economic simulation. Expert Review of Pharmacoeconomics & Outcomes Research, 1-11. https://doi.org/10.1080/14737167.2026.2757915

Vancouver

Önder AH, Çatlı MM, Keskin O. Nivolumab dose stewardship in routine oncology practice: a real-world health-economic simulation. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-11. doi:10.1080/14737167.2026.2757915

BibTeX
@article{nder2026,
  author = {Önder, Arif Hakan and Çatlı, Mehmet Mutlu and Keskin, Olgun},
  title = {Nivolumab dose stewardship in routine oncology practice: a real-world health-economic simulation},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  pages = {1--11},
  doi = {10.1080/14737167.2026.2757915}
}
Kostenlos starten →